Biomarker, Phenotyping and Therapeutics for Asthma
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 1736
Editor
Special Issue Information
Dear Colleagues,
Asthma is one of the most prevalent chronic airway diseases worldwide, characterised by marked clinical variability and substantial biological heterogeneity. Despite advances in our understanding, the diagnosis of asthma remains challenging, with no single definitive test, contributing to misdiagnosis and inappropriate treatment. Furthermore, although precision medicine has emerged for severe asthma through the introduction of biologic therapies, this applies to only a minority of patients; the majority continue to be managed with one-size-fits-all approaches that overlook the heterogeneity of individual disease endotypes.
This Special Issue seeks to bring together cutting-edge mechanistic and translational research that bridges fundamental biology with clinical application. We welcome studies that (i) identify and validate novel biomarkers for asthma diagnosis, endotyping and disease monitoring; (ii) provide experimental insights into asthma pathophysiology across immune, epithelial and airway mechanical pathways; (iii) apply multi-omics, exhaled breath analysis and advanced physiological measures to refine phenotyping and uncover therapeutic targets; and (iv) explore novel molecular pathways and therapeutic strategies.
Dr. Ran Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- allergy
- biomarkers
- pathogenesis
- exhaled breath
- multi-omics
- lung physiology
- phenotyping
- endotypes
- therapeutic targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
